These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 16504957)

  • 21. Safety and efficacy of an induction dose of pegylated interferon alpha-2a on early hepatitis C virus kinetics in HIV/HCV co-infected patients: the CORAL-1 multicentre pilot study.
    Tural C; Solà R; Rubio R; Santín M; Planas R; Quereda C; Berenguer J; Montes-Ramírez M; Clotet B;
    J Viral Hepat; 2007 Oct; 14(10):704-13. PubMed ID: 17875005
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Successful treatment with peginterferon alfa-2b of HBeAg-positive HBV non-responders to standard interferon or lamivudine.
    Flink HJ; Hansen BE; Heathcote EJ; Feinman SV; Simsek H; Karayalcin S; Mach T; Leemans WF; de Man RA; Verhey E; Schalm SW; Janssen HL;
    Am J Gastroenterol; 2006 Nov; 101(11):2523-9. PubMed ID: 17029610
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interferon and ribavirin combination therapy for chronic hepatitis C in human immunodeficiency virus-infected patients with congenital coagulation disorders.
    Sauleda S; Juárez A; Esteban JI; Altisent C; Ruiz I; Puig L; Esteban R; Guardia J
    Hepatology; 2001 Nov; 34(5):1035-40. PubMed ID: 11679976
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C.
    Reddy KR; Wright TL; Pockros PJ; Shiffman M; Everson G; Reindollar R; Fried MW; Purdum PP; Jensen D; Smith C; Lee WM; Boyer TD; Lin A; Pedder S; DePamphilis J
    Hepatology; 2001 Feb; 33(2):433-8. PubMed ID: 11172346
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Efficacy and safety of pegylated-interferon plus ribavirin in HIV-infected patients co-infected with hepatitis C virus in clinical practice: a 32 cases observational follow-up].
    Seydi M; Morlat P; Bonnet F; Rambeloarisoa J; Bernard N; Lacoste D; Bonarek M; Trimoulet P; Ramanampamonjy R; Lafon ME; Dramé M; Beylot J
    Rev Med Interne; 2005 Apr; 26(4):280-7. PubMed ID: 15820563
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Predictive value of early virological response to treatment with different interferon-based regimens plus ribavirin in patients with chronic hepatitis C.
    Napoli N; Giannelli G; Parisi CV; Antonaci A; Maddalena G; Antonaci S
    New Microbiol; 2005 Jan; 28(1):13-21. PubMed ID: 15782622
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C. The Hepatitis C Intervention Therapy Group.
    Glue P; Rouzier-Panis R; Raffanel C; Sabo R; Gupta SK; Salfi M; Jacobs S; Clement RP
    Hepatology; 2000 Sep; 32(3):647-53. PubMed ID: 10960463
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Pegylated interferon alpha 2a in treating chronic hepatitis B patients].
    Tian YL; Zhao W; Shen L; Liu W; Chang JB; Fang ZX; Yin WW; Wang L; Sun XB; Yang YJ
    Zhonghua Gan Zang Bing Za Zhi; 2006 Nov; 14(11):806-10. PubMed ID: 17125604
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Continuous low-dose interferon-alpha therapy for HIV-related immune thrombocytopenic purpura.
    Northfelt DW; Charlebois ED; Mirda MI; Child C; Kaplan LD; Abrams DI
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Jan; 8(1):45-50. PubMed ID: 8548345
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative study concerning the efficacy of Peg-IFN alpha-2a versus Peg-IFN alpha-2b on the early virological response (EVR) in patients with chronic viral C hepatitis.
    Sporea I; Danila M; Sirli R; Popescu A; Laza A; Baditoiu L
    J Gastrointestin Liver Dis; 2006 Jun; 15(2):125-30. PubMed ID: 16802006
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The use of different Peg-interferon alpha-2b regimens plus ribavirin in HCV-1b-infected patients after rapid virological response does not affect the achievement of sustained virological response.
    Napoli N; Giannelli G; Antonaci A; Antonaci S
    J Viral Hepat; 2008 Apr; 15(4):300-4. PubMed ID: 18307592
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PEGylated interferon alfa-2b and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis.
    Cacoub P; Saadoun D; Limal N; Sene D; Lidove O; Piette JC
    Arthritis Rheum; 2005 Mar; 52(3):911-5. PubMed ID: 15751068
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Early antiviral treatment of hepatitis C virus recurrence after liver transplantation in HIV-infected patients.
    Castells L; Esteban JI; Bilbao I; Vargas V; Allende H; Ribera E; Piron M; Sauleda S; Len O; Pahissa A; Esteban R; Guardia J; Margarit C
    Antivir Ther; 2006; 11(8):1061-70. PubMed ID: 17302376
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pegylated Interferon alfa-2a monotherapy results in suppression of HIV type 1 replication and decreased cell-associated HIV DNA integration.
    Azzoni L; Foulkes AS; Papasavvas E; Mexas AM; Lynn KM; Mounzer K; Tebas P; Jacobson JM; Frank I; Busch MP; Deeks SG; Carrington M; O'Doherty U; Kostman J; Montaner LJ
    J Infect Dis; 2013 Jan; 207(2):213-22. PubMed ID: 23105144
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A randomized phase II study comparing four different interferon therapies in patients with recalcitrant condylomata acuminata.
    Trizna Z; Evans T; Bruce S; Hatch K; Tyring SK
    Sex Transm Dis; 1998 Aug; 25(7):361-5. PubMed ID: 9713916
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of pegylated interferon alfa-2b in moderate COVID-19: A phase II, randomized, controlled, open-label study.
    Pandit A; Bhalani N; Bhushan BLS; Koradia P; Gargiya S; Bhomia V; Kansagra K
    Int J Infect Dis; 2021 Apr; 105():516-521. PubMed ID: 33713817
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase I trial of interferon alfa-n3 in early-stage human immunodeficiency virus type 1 disease: evidence for drug safety, tolerance, and antiviral activity.
    Skillman DR; Malone JL; Decker CF; Wagner KF; Mapou RL; Liao MJ; Testa D; Meltzer MS
    J Infect Dis; 1996 May; 173(5):1107-14. PubMed ID: 8627061
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lack of efficacy of low dose oral interferon alfa in symptomatic HIV-1 infection: a randomised, double blind, placebo controlled trial.
    Katabira ET; Sewankambo NK; Mugerwa RD; Belsey EM; Mubiru FX; Othieno C; Kataaha P; Karam M; Youle M; Perriens JH; Lange JM
    Sex Transm Infect; 1998 Aug; 74(4):265-70. PubMed ID: 9924466
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of alpha-interferon treatment for chronic hepatitis C in HIV-infected patients. HIV-Hepatitis Spanish Study Group.
    Soriano V; García-Samaniego J; Bravo R; Castro A; Odriozola PM; González J; Colmenero M; Carballo E; Suárez D; Llibre JM
    J Infect; 1995 Jul; 31(1):9-13. PubMed ID: 8522850
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 5% Imiquimod cream for external anogenital warts in HIV-infected patients under HAART therapy.
    Cusini M; Salmaso F; Zerboni R; Carminati G; Vernaci C; Franchi C; Locatelli A; Alessi E
    Int J STD AIDS; 2004 Jan; 15(1):17-20. PubMed ID: 14769165
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.